Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.

Pharmaceutical Technology

18. F. Duran Reynals, "Exaltation de l'Activité du Virus Vaccinal Par les Extraits de Certains Organes," Comptes Rendus Hebdomadaires de Séances et Mémoires de la Société de Biologie. 99, 6–7 (1928).

19. A. Claude and F. Duran-Reynals, "Chemical Properties of the Non-purified Spreading Factor from Testicle," J Exp Med. 65 (5), 661–670 (1937).

20. F. Duran-Reynals, "A Spreading Factor in Certain Snake Venoms and its Relation to their Mode of Action," J. Exp. Med. 69 (1), 69–81 (1939).

21. K. Meyer, "Hyaluronidases," in: The Enzymes, P.D. Boyer Ed., (Academic Press, New York, NY, 3rd edition, 1971), pp. 307–320.

22. K. Meyer, P. Hoffman, and A. Linker, "Hyaluronidases," in The Enzymes, P.D. Boyer, H. Lardy, and K. Myrback, Eds. (Academic Press, New York, NY, 2nd ed., 1960), pp.447–460.

23. R.G. Williams, "The Effects of Continuous Local Injection of Hyaluronidase on Skin and Subcutaneous Tissue in Rats," Anat. Rec. 122 (3), 349–361 (1955).

24. K. Pillwein et al., "Hyaluronidase Additional to Standard Chemotherapy Improves Outcome for Children with Malignant Brain Tumors," Cancer Lett. 131 (1), 101–108 (1998).

25. A.H. Eberhart, C.R. Weiler, and J.C. Erie, "Angioedema Related to the Use of Hyaluronidase in Cataract Surgery," Am. J. Ophthalmol. 138 (1), 142–143 (2004).

26. R.A. Harrison and S.J. Gaunt, "Multiple Forms of Ram and Bull Sperm Hyaluronidase Revealed by Using Monoclonal Antibodies," J. Reprod. Fertil. 82 (2), 777–785 (1988).

27. R.A. Harrison, "Hyaluronidase in Ram serum. Quantitative Determination and Isolation of Multiple Forms," Biochem J. 252 (3), 865–874 (1988).

28. H.Tint and R. Bogash (American Home Products), "Hyaluronidase," US Patent 2676139, Sept. 1, 1950.

29. H.E. Alburn et al. (American Home Products), "Stabilized Hyaluronidase Solution Containing Calcium Chloride, US Patent 2795529, June 11, 1957.

30. C.L. Borders and M.A. Raftery, "Purification and Partial Characterization of Testicular Hyaluronidase," J. Biol. Chem. 243 (13), 3756–3762 (1968).

31. W.F. Lathrop et al., "cDNA Cloning Reveals the Molecular Structure of a Sperm Surface Protein, PH-20, Involved in Sperm-egg Adhesion and the Wide Distribution of its Gene among Mammals,"J. Cell. Biol. 111 (6 Pt 2), 2939–2949 (1990).

32. M. Gmachl and G. Kreil, "Bee Venom Hyaluronidase is Homologous to a Membrane Protein of Mammalian Sperm," Proc. Natl. Acad. Sci. USA 90 (8), 3569–3573 (1993).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here